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ABSTRACT 
Objectives 
To compare overall (OS), cancer-specific (CSS), recurrence free survival (RFS) and post-
operative renal function among patients affected by upper tract urothelial carcinoma (UTUC) 
of the distal (lower lumbar and pelvic) ureter, electively treated with segmental resection and 
termino-terminal anastomosis (TT) vs bladder cuff removal and ureteral re-implantation 
(RR). 
Patients and methods 
A multicentre retrospective study, including 84 patients diagnosed with UTUC of the distal 
ureter and treated with TT or RR, is presented. The primary endpoint was to compare TT and 
RR in terms of OS, CSS and RFS. As a secondary outcome we compared the post-operative 
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creatinine values as an index of renal function in the two groups. 
Results 
Out of 521 patients with UTUC, 65 (77.4%) and 19 (22.6%) patients underwent RR and TT, 
respectively. Pre- and post-operative characteristics were not statistically different between 
the two groups. The median follow-up period was 22.7 months. Patients treated with TT and 
those treated with RR did not show significantly different 5yOS, 5yCSS and 5yRFS (73.7 vs 
92.3%, p = 0.052, 94.7 vs 95.4%, p = 0.970, and 63.2 vs 53.9%, p = 0.489, respectively). No 
difference in post-operative creatinine variation emerged in association with the surgical 
technique (p = 0.411). 
Conclusion 
Patients treated with TT or RR for UTUC showed comparable OS, CSS, RFS and post-
operative renal function. Our data suggest that the bladder cuff removal is not imperative in 
the treatment of distal ureteral UTUC, and TT can be a safe solution in selected cases. 
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INTRODUCTION  
Upper tract urothelial carcinoma (UTUC) is a rare malignancy [1, 2] that can be located in 
the pyelocaliceal cavities and, although less commonly, in the ureter [3]. Despite the fact that 
radical nephroureterectomy (RNU) with bladder cuff removal is currently considered as the 
standard treatment [4], recently kidney-sparing surgery (KSS), and in particular open or 
laparoscopic segmental ureterectomy (SU), has been proposed in selected cases such as 
solitary kidney, chronic kidney disease and synchronous bilateral disease, together with 
endoscopic and percutaneous procedures [5].  
It is commonly accepted in reconstructive surgery that short and uncomplicated proximal 
ureteral defects can be treated with direct ureteroureterostomy, while ureteroneocystostomy 
or ureteroureterostomy can be performed for distal ones, guarantying a tension-free repair [6].  
Short term overall (OS), cancer-specific (CSS) and recurrence free survival (RFS) in a recent 
meta-analysis in patients treated for UTUC did not significantly differ between SU and RNU 
[7]. Moreover, RNU could be associated with a significant decrease of renal function in 
comparison with SU. Data for survival and functional outcome are missing on a long-term 
follow-up and even less is known about functional outcomes and survival among patients 
undergoing different surgical techniques of ureteral anastomosis after SU for UTUC.  
Considering this gap in literature, the aim of our study was to compare the OS, CSS and RFS 
among patients undergoing surgery for UTUC, electively treated with segmental resection of 
the distal ureter and termino-terminal anastomosis (TT) vs bladder cuff removal and ureteral 
reimplantation (RR). As a secondary endpoint, the impact of the surgical technique on post-
operative renal function was evaluated.  
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PATIENTS AND METHODS  
Study design 
Data from patients treated for UTUC in six Italian tertiary referral centres (Bologna, Genoa, 
Milan, Palermo, Trieste, Turin) from January 2003 to December 2013 were collected. All 
consecutive patients underwent TT or RR for UTUC of the distal (lower lumbar and pelvic) 
ureter were included in the analysis. All patients were diagnosed with UTUC at computed 
tomography (CT) or magnetic resonance (MR) imaging. Preoperative ureteroscopy with 
biopsy was performed when indicated for doubtful imaging. Other preoperative data included 
age, gender, smoking status, creatinine value (mg/dl), symptoms, urine cytology, tumour site, 
hydronephrosis, stage and grade of previous bladder tumour. Patients with a history of 
previous UTUC, metastatic disease, radical cystectomy or other malignancies were excluded. 
Patients were treated with SU and TT or RR according to tumour location. Pathological data 
included T and N category, carcinoma in situ detection, grade, number of lymph nodes 
dissected, lymph vascular invasion, tumour necrosis, surgical margin status and the presence 
of concomitant bladder cancer. Patients underwent follow-up every 3 months the first year 
after surgery, 4 months the second year, 6 months from the third to the fifth year, and then 
annually, according to the most recent international guidelines [8]. Creatinine plasmatic 
levels, recurrence and the necessity of chemotherapy were recorded.  
 
Statistical analysis 
Statistical analysis was performed by one of the authors (MS). Patient characteristics were 
compared at baseline and the end of the follow-up period, using the Student’s t-test or Mann-
Whitney U test for continuous variables and χ2 for categorical variables. The primary 
outcome of the current study was to compare TT and RR in terms of OS, CSS and RFS. Thus 
un-adjusted 5-year (5y)OS curves of the two groups were compared by using the Kaplan–
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Meier method, while CSS and RFS were compared by using the cumulative incidence 
method [9]. A multivariate Cox regression adjusted for technique, age, gender, chemotherapy 
and recurrence was used to estimate Hazard Ratios (HR). As a secondary outcome, we 
investigated the delta creatinine (post-operative minus pre-operative creatinine) in the two 
groups. In particular, a multivariate Cox regression adjusted for technique, age, gender, 
tumour side and localization, hydronephrosis, tumour pathological stage, chemotherapy and 
pre-operative creatinine was used to calculate HR. Post-hoc power analyses for unadjusted 
analyses were performed by using power calculation methods described by Freedman [10], 
Schoenfeld [11] and Latouche [12]. In particular, we computed if with our study sample we 
were able to observe an HR of 8.7, 0.01, and 0.05 for 5yOS, 5yCSS, and 5yRFS between TT 
and RR, respectively. Statistical analyses were performed with R v3.3.3. A p value < 0.05 
was considered as statistically significant. 
 
RESULTS  
We retrospectively collected the data of 521 patients treated for UTUC from 2003 to 2013 in 
six selected Italian centres. Overall, 84 patients underwent segmental resection of the ureter 
for a distal ureteral UTUC; 65 (77.4%) and 19 (22.6%) patients underwent RR and TT, 
respectively. In terms of pre-operative characteristics, only the localization of the tumour and 
the performance of an endoscopic biopsy prior to surgery showed statistically different 
distribution among patients treated with RR and TT (p < 0.001 and p = 0.046, respectively; 
Table 1). Overall only four cases of perioperative complications were reported: three 
Clavien-Dindo grade 2 (fever requiring antibiotics) and one grade 3 (intravesical bleeding 
requiring endoscopic treatment). Four (3 after RR and 1 after TT) ascertained anastomotic 
strictures were reported, but endoscopic correction was required in only two of them. 
Post-operative pathological characteristics including stage, grade, number of lymph nodes 
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dissected, lymphovascular invasion, necrosis, positive surgical margins and presence of 
concomitant bladder cancer were not statistically different between the two groups (Table 2). 
The median follow-up period of the study population was 22.7 months (range 0.5 - 120 
months). Overall, 9 (10.7%) and 24 (28.6%) patients locally had ureteral and bladder 
recurrence, while 4 (4.8%) patients developed metastatic disease, showing a comparable 
distribution between the two groups (p = 0.061, Table 3). No statistically significant 
difference in terms of 5yOS, 5yCSS and 5yRFS was detected among patients treated with TT 
and RR (73.7 vs 92.3%, p = 0.052, 94.7 vs 95.4%, p = 0.970, and 63.2 vs 53.9%, p = 0.489); 
(Figure 1) respectively. Post hoc power analyses revealed that for expected HRs we had a 
statistical power of 0.80. At the multivariable adjusted analysis the type of reconstructive 
technique, gender and age were not significantly associated with OS, CSS and RFS: post-
operative chemotherapy was the only significant determinant for CSS with a HR of 9.86 
(95%CI 1.31 - 74.42, p = 0.03; Figure S1).  
No statistically significant difference was observed for post-operative creatinine variation 
among patients treated with TT and RR (delta creatinine 0.0 ± 0.3 and 0.1 ± 0.2 mg/dl, 
respectively; p = 0.383). In the adjusted analysis, statistically significant determinants for 
post-operative creatinine variation were preoperative creatinine level (HR 0.35, 95%CI 0.10 - 
0.60; p = 0.010), male gender (HR 0.31, 95%CI 0.10 - 0.52; p = 0.006), left side location (HR 
0.37, 95%CI 0.09 - 0.64; p = 0.012) and pT3 disease (HR 0.50, 95%CI 0.09 - 0.91; p = 
0.020), irrespective of the surgical technique (p = 0.411; Figure 2).  
 
DISCUSSION 
In this multicentre retrospective study we compared the OS, CSS and RFS of two different 
ureteral reconstruction techniques after SU for distal ureteral UTUC. Interestingly, patients 
treated with TT and RR showed comparable 5yOS, 5yCSS and 5yRFS.  
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Although it is known that up to 70% of ureteral tumours occur in the distal ureter, 25% in the 
mid-ureter, and 5% in the proximal ureter [13], RNU is widely indicated as the standard 
treatment for UTUC, regardless of tumour localization [4], and the removal of the entire 
ureter seems to be mandatory. In fact, it has been discussed that total excision of the distal 
ureter with its intramural portion, including the ipsilateral ureteric orifice and bladder cuff, is 
essential for optimal treatment of UTUC [14]. Clearly the rationale for the indication of 
excising all the affected upper urinary tract derives from the observation of a high disease 
recurrence rate in the remaining ureteral stump after a simple nephrectomy [15].  
However, chronic kidney disease has been reported in 52% of patients with UTUC at 
diagnosis, with this rate significantly increasing to 78% after RNU with a median relative 
reduction in renal function of 21% [16] and an estimated glomerular filtration rate decrease of 
9.32 ml/1.73 m
2
 (p = 0.007) after RNU in comparison with SU [7]. Nowadays, KSS is 
acceptable in selected cases of anatomical or functional solitary kidney, bilateral disease or 
severe renal insufficiency to avoid the morbidities frequently following RNU [17]. KSS and 
RNU have been compared on heterogeneous patients’ population and the available data are 
therefore highly variable and difficult to adapt to common clinical practice [18].  
Recently, a meta-analysis published by Fang et al. in 2016 found no significant differences 
between SU and RNU in terms of CSS (unadjusted HR 0.90, 95%CI 0.73 - 1.11; p = 0.33) 
[7]. Although some concerns have been raised about the dissimilar distribution of T stage and 
grade between the two treatment groups, no significant differences were detected in terms of 
CSS in patients with non-muscle invasive UTUC [19] and high-grade disease [20]. Also OS 
(HR 0.98, 95%CI 0.63 - 1.53; p = 0.93) and RFS (HR 1.06, 95%CI 0.76 - 1.48; p = 0.72) 
appeared to be comparable between SU and RNU [7].  
Translating the experience from the RNU to the KSS, it is common practice to excise the 
bladder cuff also for the distal ureteral UTUC with consequent ureteral re-implantation. 
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However it has not yet clearly been demonstrated if any differences exist  for functional and 
oncological outcomes among patients treated with RR and TT for UTUC.  
Both ureteroneocystostomy or ureteroureterostomy have been suggested with good outcomes 
for benign and malignant ureteral diseases. Wenske et al [21] reported excellent functional 
outcomes without significant morbidity in a population of 100 patients undergoing ureteral 
re-implantation by psoas-hitch, Boari flap, or ureteroneocystostomy for benign ureteral 
obstruction or UTUC, with no statistically significant difference between the three different 
surgical techniques. On the other hand, open end-to-end ureteroureterostomy resulted to be 
effective and safe in treating iatrogenic lower ureteral injury at 33.7 months median follow-
up [22]. A ureteral patency rate of 96% has also been reported in patients treated with open 
ureteroneocystostomy or ureteroureterostomy with no significant difference adopting a 
laparoscopic approach (p = 0.544) at a mean follow-up of 43 months [23]. Moreover 
ureteroureterostomy showed significantly less estimated blood loss (p < 0.001) and lower 
incidence of vesicoureteral reflux (grade I) on cystography (p = 0.031) in comparison with 
ureteroneocystostomy at a follow-up of 36.5 months [24].  
In case of UTUC the different reconstruction techniques are often analysed all together and, 
to our knowledge, there are no comparative studies between RR and TT in terms of oncologic 
outcomes. Interestingly in our experience TT and RR showed similar 5yOS, 5yCSS and 
5yRFS (Figure 1), quite better than those after RNU (data not shown), with a low rate of 
ureteral (10.7%) and bladder (28.6%) recurrence (Table 3). Accordingly, a 5yOS of 40 – 
72%, 5yCSS of 54 – 90%, 5yRFS of 28 - 84% and an intravesical recurrence-free survival of 
54 - 69% have been reported in patients treated with SU for UTUC [7].  
There is no consensus on the role of tumour location in terms of oncologic outcomes for 
ureteral cancer: in our experience the choice of the reconstructive technique primarily 
depended on the tumour location and this reflected its different distribution in the two groups 
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(RR vs TT). This could also explain the different (although not significant) distribution of 
recurrence reported in the two groups. 
We also detected a comparable distribution of post-operative pT stage and grade, reducing 
the concern about selection bias. Noteworthy, the rate of positive surgical margin is similar 
between the groups with a slightly higher rate in the RR group in contrast with the common 
thought.  
Considering the post-operative variation of renal function in terms of serum creatinine levels, 
we found that pre-operative creatinine, male gender, pT3 stage and left side were associated 
with a significant HR for post-operative creatinine variation. This observation could be 
partially explained considering that in our population male patients and those with left side 
tumours also had higher pre-operative creatinine levels (although not statistically significant). 
Conversely pathological stage had already been associated to renal function [25]. 
Finally, the main limitation of our study is its retrospective design and the small sample size, 
partially due to the rarity of the disease. Consequently some probably interesting data, such as 
the dimensions of the disease at CT scan or previous intravesical chemotherapy, were not 
available. No pathological data on the concomitant or recurrent bladder cancer and the 
chemotherapy protocol were available. Another limitation is the lack of data on 
administration of postoperative instillation after surgery at the Centres included in our study. 
On the contrary the main strength of our study is its multicentre approach with a validated 
and shared follow-up scheme. Instead an exhaustive comparison between RNU and SU in 
terms of oncologic and functional outcomes was beyond the intents of this study. 
In conclusion, we report that patients treated with TT or RR for UTUC showed comparable 
5yOS, 5yCSS and 5yRFS. Moreover, no significant differences were found in terms of post-
operative creatinine variation between the two surgical techniques. Our results could suggest 
that the bladder cuff removal is not imperative in the treatment of distal ureteral UTUC, and 
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TT can be a safe solution when feasible in selected cases of common clinical practice. 
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LEGENDS TO ILLUSTRATIONS 
Figure 1. Comparison between RR and TT techniques in terms of 5-years OS (A), CSS (B) 
and RFS (C). 
 
Figure 2. Multivariate Cox regression adjusted analysis for post-operative creatinine 
variation. 
 
Figure S1. Multivariate Cox regression adjusted analysis for OS (A), CSS (B) and RFS (C). 
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Table 1. Pre-operative descriptive characteristics of the study population. 
Variable Total RR TT p-value 
Patients 84 65 (77.4) 19 (22.6)  
Age, yr 69.5 ± 9.1 69.8 ± 9.7 68.7 ± 6.8 0.651 
Gender 
    Male 65 (77.4) 52 (80.0) 13 (68.4) 
0.454 
    Female 19 (22.6) 13 (20.0) 6 (31.6) 
Smoking status – 30 pts 
    No 12 (40.0) 11 (45.8) 1 (16.7) 
0.402 
    Yes 18 (60.0) 13 (54.2) 5 (83.3) 
Preoperative serum creatinine, mg/dl 1.04 ± 0.37 1.04 ± 0.39 1.05 ± 0.34 0.964 
Symptoms – 43pts 
    No 15 (34,9%) 11 (32.4) 4 (44.4) 
0.777 
    Yes 28 (65,1%) 23 (67.6) 5 (55.6) 
Prior endoscopic biopsy 
    No 65 (77.4) 54 (83.1) 11 (57.9) 
0.046 
    Yes 19 (22.6) 11 (16.9) 8 (42.1) 
        Negative 4 (21.1) 3 (27.3) 1 (12.5) 
0.834 
        Positive 15 (78.9) 8 (72.7) 7 (87.5) 
Prior urine cytology 
    No 64 (76.2) 50 (76.9) 14 (73.7) 
0.988 
    Yes 20 (23.8) 15 (23.1) 5 (26.3) 
        Negative 12 (60.0) 11 (73.3) 1 (20.0) 
0.114 
        Positive 8 (40.0) 4 (26.7) 4 (80.0) 
Tumor localization 
    Intramural 27 (32.1) 27 (41.5) 0 (0.0) 
< 0.001     Pelvic 46 (54.8) 33 (50.8) 13 (68.4) 
    Lower lumbar 11 (13.1) 5 (7.7) 6 (31.6) 
Tumor side 
    Right 31 (36.9) 26 (40.0) 5 (16.3) 
0.414 
    Left 53 (63.1) 39 (60.0) 14 (73.7) 
Hydronephrosis –  44 pts 
    No 11 (25.0) 11 (32.4) 0 (0.0) 
0.097 
    Yes 33 (75.0) 23 (67.6) 10 (100.0) 
History of bladder tumor 
    No 54 (64.3) 40 (61.5) 14 (73.7) 
0.484 
    Yes 30 (35.7) 25 (38.5) 5 (26.3) 
Prior bladder tumor pT stage – 29 pts 
    pTa 11 (36.6) 9 (36.0) 2 (50.0) 
0.663     pT1 14 (46.6) 12 (48.0) 2 (50.0) 
    CIS 4 (13.8) 4 (16.0) 0 (0.0) 
Prior bladder tumor grade – 28 pts 
    G1 7 (25.0) 5 (20.8) 2 (50.0) 
0.285     G2 8 (28.6) 8 (33.3) 0 (0.0) 
    G3 13 (46.4) 11 (45.8) 2 (50.0) 
Continuous variables are expressed as mean ± SD; nominal variables are expressed as No. (%) 
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Table 2. Pathological characteristics. 
Variable Total RR TT p-value 
Patients 84 65 (77.4) 19 (22.6)  
Pathological T-stage 
pT0 2 (2.4) 1 (1.5) 1 (5.3) 
0.721 
pTa 30 (35.7) 21 (32.3) 9 (47.4) 
pT1 21 (25.0) 17 (26.2) 4 (21.0) 
pT2 19 (22.6) 16 (24.6) 3 (15.8) 
pT3 11 (13.1) 9 (13.8) 2 (10.5) 
CIS 1 (1.2) 1 (1.5) 0 (0.0) 
CIS associated 
No 81 (96.4) 62 (95.4) 19 (100.0) 
0.802 
Yes 3 (3.6) 3 (4.6) 0 (0.0) 
Lymph node dissection 
No 65 (77.4) 48 (73.8) 17 (89.5) 
0.262 
Yes 19 (22.6) 17 (26.2) 2 (10.5) 
No. lymph nodes dissected 1.1 ± 2.9 1.4 ± 3.2 0.1 ± 0.2 0.089 
Pathological N-stage 
pN0 17 (20.2) 15 (23.1) 2 (10.5) 
0.334 pN1 2 (2.4) 2 (3.1) 0 (0.0) 
pNx 65 (77.4) 48 (73.8) 17 (89.5) 
Grade – 81 pts 
G1 12 (14.8) 7 (11.1) 5 (27.8) 
0.173 G2 21 (25.9) 16 (25.4) 5 (27.8) 
G3 48 (59.3) 40 (63.5) 8 (44.4) 
Limph vascular invasion – 46 pts 
No 42 (91.3) 32 (91.4) 10 (90.9) 
0.576 
Yes 4 (8.7) 3 (8.6) 1 (9.1) 
Necrosis – 83 pts 
No 80 (96.4) 62 (96.9) 18 (94.7) 
0.794 
Yes 3 (3.6) 2 (3.1) 1 (5.3) 
Surgical margins 
Negative 69 (82.1) 55 (84.6) 14 (73.7) 
0.451 
Positive 15 (17.9) 10 (15.4) 5 (26.3) 
Concomitant bladder cancer 
No 67 (79.8) 49 (75.4) 18 (94.7) 
0.128 
Yes 17 (20.2) 16 (24.6) 1 (5.3) 
Continuous variables are expressed as mean ± SD; nominal variables are expressed as No. (%). 
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Table 3. Post-operative follow-up. 
Variable Total RR TT p-value 
Patients 84 65 (77.4) 19 (22.6)  
Follow-up period, mo 
22.7 
(14.0 – 29.0) 
21.5 
(12.2 – 33.3) 
25.2 
(12.4 – 39.9) 
0.769 
Post-operative creatinine, mg/dl 1.1 ± 0.3 1.1 ± 0.3 1.0 ± 0.3 0.580 
Delta creatinine, mg/dl 0.1 ± 0.3 0.1 ± 0.2 0.0 ± 0.3 0.383 
Recurrence 
No 47 (56,0%) 35 (53.8) 12 (63.2) 
0.648 
Yes 37 (44,0%) 30 (46.2) 7 (36.8) 
   Omolateral 7 (18,9%) 3 (10.0) 4 (57.1) 
0.061 
   Contralateral 1 (2,7%) 1 (3.3) 0 (0.0) 
   Bilateral 1 (2,7%) 1 (3.3) 0 (0.0) 
   Vesical 24 (64,9%) 22 (73.3) 2 (28.6) 
   Metastasis 4 (10,8%) 3 (10.0) 1 (14.3) 
Systemic chemotherapy 
No 76 (90,5%) 59 (90.8) 17 (89.5) 
0.783 
Yes 8 (9,5%) 6 (9.2) 2 (10.5) 
Continuous variables are expressed as median (95%CI) or mean ± SD; nominal variables are expressed as No. 
(%). 
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